secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-09-25T23:59:59+00:00
Accession:  0001213900-24-081799
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics posts updated presentation detailing Phase 3 plans for tecarfarin in LVAD and other indications
--------------------------------------------------------------------------------

- Phase 3 trial planned for LVAD patients: 440 patients randomized 1:1 tecarfarin vs warfarin for 26 weeks.
- Tecarfarin has FDA Orphan Drug Designation for LVAD and ESKD+AFib, and Fast Track for ESKD+AFib.
- Cash $5.0M, no debt, market cap $14.2M as of 9/18/24; insider ownership 42%.
- Phase 2/3 data showed tecarfarin achieved higher TTR (70% vs 67%, p=0.04) and fewer thrombotic events than warfarin.
- Presentation also outlines targeted indications: MHV patients with difficult-to-control TTR or warfarin resistance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024081799/0001213900-24-081799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024081799/ea0215596-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-081799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer